Related Experiment Video
Updated: Jul 14, 2026
14:45
Transgenic Rodent Assay for Quantifying Male Germ Cell Mutant Frequency
Published on: August 6, 2014
Kit expression in male germ cell tumors
M Nikolaou1, C Valavanis, G Aravantinos
1Second Department of Internal Medicine-Propaedeutic, Attikon Hospital, Athens University Medical School, Greece. m_nikolaou@panafonet.gr
Anticancer Research
|June 29, 2007
Summary
KIT receptor tyrosine kinase is highly expressed in most seminomas and combined tumors, but rarely in non-seminomatous germ cell tumors. This finding suggests potential therapeutic strategies for chemoresistant germ cell tumors overexpressing KIT.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- KIT receptor tyrosine kinase (RTK) signaling is crucial for germ cell development and survival.
- Aberrant KIT signaling is implicated in oncogenesis, particularly in cells expressing the receptor.
- Understanding KIT expression in germ cell tumors (GCTs) is vital for potential targeted therapies.
Purpose of the Study:
- To investigate KIT expression in patients with germ cell tumors (GCTs).
- To correlate KIT expression with clinical characteristics of GCT patients.
- To explore the potential of KIT as a therapeutic target in GCTs.
Main Methods:
- Analysis of 173 formalin-fixed, paraffin-embedded GCT samples using immunohistochemistry for KIT.
- Quantification of KIT-positive cells by an independent pathologist, with positivity defined as >10% membranous or cytoplasmic staining.
- Correlation of KIT expression with GCT histology, stage, and treatment response.
Main Results:
- KIT expression was detected in 77.5% of pure seminomas and 48.6% of malignant teratoma combined (MTC) GCTs.
- KIT positivity was significantly higher in seminomas compared to anaplastic seminomas (p < 0.001).
- KIT expression strongly correlated with seminomatous histology but not with tumor stage or treatment response.
Conclusions:
- KIT is predominantly expressed in seminomas and seminomatous components of mixed GCTs.
- KIT expression is limited in anaplastic seminomas and rare in non-seminomatous GCTs.
- Targeting KIT with tyrosine kinase inhibitors may offer a therapeutic avenue for chemoresistant GCTs with KIT overexpression.
